dimenhydrinate Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
N-methylated xanthine derivatives	901	523-87-5

Description:

Molecule	Description
Synonyms: dimenhydrinate andramine chloranautine diamarin diphenhydramine 8-chlorotheophyllinate diphenhydrinate dramamine menhydrinate theohydramine	A drug combination that contains diphenhydramine and theophylline. It is used for treating VERTIGO, MOTION SICKNESS, and NAUSEA associated with PREGNANCY. Molecular weight: 469.97 Formula: C24H28ClN5O3 CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: ALOGS: ROTB: None

Drug dosage:

None

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
May 31, 1972	FDA	ALRA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Urine abnormality	366.87	15.29	131	24943	5463	46655525
Lymphocyte count decreased	289.62	15.29	177	24897	25412	46635576
Urine leukocyte esterase positive	247.36	15.29	80	24994	2455	46658533
Red blood cells urine positive	185.94	15.29	65	25009	2542	46658446
Blood urine present	175.92	15.29	99	24975	12183	46648805
White blood cells urine positive	170.98	15.29	69	25005	4031	46656957
Urinary sediment present	159.66	15.29	53	25021	1767	46659221
Crystal urine present	128.01	15.29	41	25033	1218	46659770
Urine ketone body present	124.86	15.29	46	25028	2096	46658892
Urine analysis abnormal	116.74	15.29	53	25021	4137	46656851
Enthesopathy	107.99	15.29	52	25022	4638	46656350
Haemoglobin urine present	103.25	15.29	30	25044	636	46660352
Red cell distribution width increased	96.70	15.29	57	25017	7647	46653341
Death	93.35	15.29	32	25042	335516	46325472
Flushing	90.20	15.29	140	24934	64474	46596514
Blood parathyroid hormone decreased	90.18	15.29	45	25029	4336	46656652
Culture urine positive	88.53	15.29	41	25033	3350	46657638
Tongue disorder	86.98	15.29	52	25022	7158	46653830
Chest discomfort	85.84	15.29	165	24909	90104	46570884
Tenosynovitis	84.99	15.29	52	25022	7463	46653525
Aplastic anaemia	82.19	15.29	50	25024	7103	46653885
Red blood cell sedimentation rate	81.44	15.29	32	25042	1741	46659247
Bacterial test	81.05	15.29	29	25045	1214	46659774
Granuloma skin	78.46	15.29	38	25036	3432	46657556
Panniculitis	76.34	15.29	44	25030	5660	46655328
Bacterial test positive	75.41	15.29	40	25034	4376	46656612
Feeling hot	73.31	15.29	96	24978	37832	46623156
Specific gravity urine decreased	73.24	15.29	21	25053	424	46660564
Lymphocyte percentage decreased	71.60	15.29	33	25041	2666	46658322
Monocyte percentage increased	66.75	15.29	24	25050	1019	46659969
Skin necrosis	66.68	15.29	47	25027	8557	46652431
Rheumatoid nodule	62.42	15.29	46	25028	8974	46652014
Body temperature increased	61.06	15.29	71	25003	24790	46636198
Eosinophil count increased	61.03	15.29	43	25031	7823	46653165
Completed suicide	59.72	15.29	5	25069	145915	46515073
Neutrophil percentage increased	59.47	15.29	29	25045	2658	46658330
Nausea	58.20	15.29	593	24481	686861	45974127
Infusion site pain	55.64	15.29	45	25029	10062	46650926
Mean cell haemoglobin concentration increased	55.44	15.29	17	25057	436	46660552
Gangrene	54.40	15.29	33	25041	4662	46656326
Arterial occlusive disease	53.71	15.29	33	25041	4771	46656217
Monocyte count decreased	51.40	15.29	23	25051	1734	46659254
Haematocrit decreased	50.35	15.29	77	24997	34980	46626008
Ulcer	50.13	15.29	54	25020	17338	46643650
Blood creatinine decreased	49.27	15.29	31	25043	4673	46656315
Red blood cell count decreased	48.76	15.29	73	25001	32550	46628438
Headache	45.39	15.29	423	24651	477929	46183059
Blood thyroid stimulating hormone increased	45.33	15.29	32	25042	5837	46655151
Intestinal pseudo-obstruction	45.15	15.29	16	25058	651	46660337
Eosinophil percentage increased	44.71	15.29	17	25057	846	46660142
Insomnia	43.02	15.29	189	24885	164735	46496253
C-reactive protein abnormal	42.90	15.29	55	25019	21215	46639773
Protein urine present	42.02	15.29	29	25045	5102	46655886
Creatinine urine decreased	41.99	15.29	11	25063	156	46660832
Blood pressure fluctuation	41.10	15.29	65	25009	30383	46630605
Heart rate increased	41.08	15.29	110	24964	74681	46586307
Tendonitis	40.57	15.29	44	25030	14233	46646755
Mean cell haemoglobin decreased	40.40	15.29	23	25051	2889	46658099
Leukocyturia	39.68	15.29	16	25058	932	46660056
Specific gravity urine increased	39.55	15.29	11	25063	198	46660790
Red blood cells urine	39.45	15.29	13	25061	423	46660565
Urine leukocyte esterase	38.91	15.29	10	25064	131	46660857
Neutrophil count increased	38.89	15.29	43	25031	14210	46646778
Arteriovenous fistula occlusion	38.80	15.29	12	25062	317	46660671
Blood thyroid stimulating hormone decreased	38.58	15.29	25	25049	3964	46657024
Alveolitis	38.00	15.29	21	25053	2492	46658496
Blue toe syndrome	37.90	15.29	12	25062	343	46660645
Myelocyte count increased	37.77	15.29	12	25062	347	46660641
Oropharyngeal pain	37.67	15.29	106	24968	74062	46586926
Product dose omission issue	37.49	15.29	22	25052	168498	46492490
Chills	37.34	15.29	125	24949	95907	46565081
Red cell distribution width decreased	37.19	15.29	15	25059	874	46660114
Loss of personal independence in daily activities	36.48	15.29	89	24985	57094	46603894
Acute kidney injury	36.28	15.29	44	25030	235811	46425177
Urticaria	36.13	15.29	142	24932	117750	46543238
Hypercalcaemia	35.68	15.29	50	25024	20996	46639992
Tri-iodothyronine free decreased	33.85	15.29	10	25064	225	46660763
Tachycardia	33.83	15.29	124	24950	99498	46561490
Basal cell carcinoma	33.74	15.29	48	25026	20439	46640549
Blood uric acid decreased	33.14	15.29	12	25062	520	46660468
Nitrite urine present	32.84	15.29	13	25061	721	46660267
Mean cell haemoglobin concentration decreased	32.41	15.29	19	25055	2521	46658467
C-reactive protein increased	31.99	15.29	86	24988	58504	46602484
Crystalluria	31.99	15.29	11	25063	409	46660579
Hyponatraemia	31.13	15.29	8	25066	101324	46559664
Bradycardia	31.00	15.29	92	24982	66206	46594782
Cardiac failure congestive	30.68	15.29	6	25068	91744	46569244
Rash pruritic	30.55	15.29	71	25003	44144	46616844
Injection site pain	30.09	15.29	10	25064	107142	46553846
pH urine increased	30.08	15.29	9	25065	212	46660776
Alanine aminotransferase abnormal	29.89	15.29	18	25056	2509	46658479
Multiple sclerosis relapse	29.50	15.29	68	25006	42057	46618931
Gastric disorder	29.35	15.29	52	25022	26653	46634335
Toxicity to various agents	29.01	15.29	43	25031	211723	46449265
Thyroxine free increased	28.95	15.29	12	25062	750	46660238
Throat irritation	28.88	15.29	54	25020	28847	46632141
Fear of injection	28.35	15.29	21	25053	4126	46656862
Infusion related reaction	27.90	15.29	118	24956	101090	46559898
Myelocyte percentage increased	27.78	15.29	8	25066	164	46660824
Oedema peripheral	27.64	15.29	27	25047	159679	46501309
Thrombocytopenia	27.47	15.29	17	25057	126564	46534424
Thyroid disorder	27.19	15.29	33	25041	12043	46648945
Drug ineffective	26.97	15.29	234	24840	677604	45983384
Monocyte count increased	26.72	15.29	22	25052	5042	46655946
Urine oxalate increased	26.51	15.29	8	25066	194	46660794
Band neutrophil percentage increased	26.21	15.29	8	25066	202	46660786
Body temperature decreased	25.99	15.29	34	25040	13375	46647613
Alanine aminotransferase increased	25.85	15.29	105	24969	88346	46572642
Oesophageal spasm	25.70	15.29	15	25059	1974	46659014
Bulimia nervosa	25.61	15.29	10	25064	535	46660453
Drug eruption	25.35	15.29	43	25031	21286	46639702
Drug interaction	25.22	15.29	44	25030	203050	46457938
Nasopharyngitis	25.17	15.29	155	24919	153843	46507145
Poor venous access	24.30	15.29	26	25048	8282	46652706
Cerebrovascular accident	24.19	15.29	12	25062	101027	46559961
Retinal depigmentation	23.89	15.29	8	25066	274	46660714
Renal failure	23.63	15.29	16	25058	113578	46547410
Band sensation	23.44	15.29	10	25064	672	46660316
Red blood cell count increased	23.40	15.29	15	25059	2335	46658653
White blood cell count decreased	22.97	15.29	120	24954	112111	46548877
Mean cell volume decreased	22.88	15.29	15	25059	2425	46658563
Synovitis	22.41	15.29	78	24996	60997	46599991
Band neutrophil count increased	22.38	15.29	8	25066	334	46660654
Seizure	22.23	15.29	20	25054	123034	46537954
Cardio-respiratory arrest	22.06	15.29	3	25071	59866	46601122
Infusion site extravasation	21.99	15.29	20	25054	5236	46655752
Heart rate decreased	21.98	15.29	51	25023	31672	46629316
Palpitations	21.71	15.29	105	24969	95154	46565834
Electrocardiogram QRS complex abnormal	21.36	15.29	7	25067	224	46660764
Vitamin B12 decreased	21.13	15.29	15	25059	2760	46658228
Psoriasis	20.93	15.29	8	25066	78596	46582392
Dizziness	20.67	15.29	276	24798	340138	46320850
Infusion site discomfort	20.40	15.29	9	25065	656	46660332
Colitis microscopic	20.03	15.29	21	25053	6535	46654453
Endometrial ablation	19.96	15.29	9	25065	691	46660297
Oesophageal pain	19.95	15.29	14	25060	2529	46658459
Lipaemic index score	19.71	15.29	5	25069	62	46660926
Skin papilloma	19.68	15.29	17	25057	4159	46656829
Gestational hypertension	19.60	15.29	13	25061	2142	46658846
Angina pectoris	19.60	15.29	44	25030	26731	46634257
Teratoma benign	19.56	15.29	5	25069	64	46660924
Confusional state	19.51	15.29	35	25039	159857	46501131
Red blood cell sedimentation rate increased	19.50	15.29	40	25034	22849	46638139
Drug abuse	19.48	15.29	5	25069	63403	46597585
Overdose	19.11	15.29	16	25058	101963	46559025
Gingival bleeding	18.76	15.29	27	25047	11612	46649376
Infusion site swelling	18.76	15.29	19	25055	5680	46655308
Psoriatic arthropathy	18.46	15.29	52	25022	36327	46624661
Cardiac failure	18.39	15.29	10	25064	79938	46581050
Creatinine urine increased	18.30	15.29	6	25068	192	46660796
Urinary retention	18.16	15.29	42	25032	26019	46634969
Infusion site scar	18.01	15.29	6	25068	202	46660786
Blood pressure increased	17.94	15.29	123	24951	126543	46534445
Immune thrombocytopenia	17.71	15.29	22	25052	8219	46652769
Renal pain	17.60	15.29	18	25056	5443	46655545
Erythema	17.53	15.29	134	24940	142686	46518302
Disease progression	17.51	15.29	14	25060	91286	46569702
Limbal swelling	17.46	15.29	4	25070	31	46660957
Neuropathy peripheral	17.36	15.29	14	25060	90879	46570109
Large intestinal ulcer haemorrhage	17.16	15.29	5	25069	107	46660881
Osteoarthritis	17.04	15.29	6	25068	62019	46598969
Klebsiella test positive	16.93	15.29	9	25065	988	46660000
Heart sounds	16.86	15.29	6	25068	247	46660741
Immature granulocyte count increased	16.73	15.29	6	25068	253	46660735
Change in seizure presentation	16.44	15.29	6	25068	266	46660722
Haemoglobin decreased	16.39	15.29	122	24952	128827	46532161
Mean cell volume increased	16.37	15.29	13	25061	2831	46658157
Urinary casts	16.16	15.29	7	25067	488	46660500
Skin ulcer	16.08	15.29	46	25028	32412	46628576
Multiple organ dysfunction syndrome	16.03	15.29	4	25070	51706	46609282
Defaecation disorder	15.93	15.29	6	25068	291	46660697
Rhinorrhoea	15.88	15.29	59	25015	47606	46613382
Dysmenorrhoea	15.86	15.29	14	25060	3524	46657464
Vaginal discharge	15.77	15.29	16	25058	4792	46656196
Thyroid stimulating immunoglobulin	15.66	15.29	4	25070	51	46660937
Skin reaction	15.65	15.29	24	25050	10922	46650066
Thirst	15.60	15.29	24	25050	10952	46650036
Productive cough	15.44	15.29	61	25013	50654	46610334
Wrong technique in product usage process	15.41	15.29	5	25069	54417	46606571

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Enthesopathy	146.37	19.61	45	6672	2861	29942900
Tenosynovitis	137.94	19.61	45	6672	3470	29942291
C-reactive protein abnormal	113.93	19.61	44	6673	5549	29940212
Tongue disorder	106.18	19.61	39	6678	4283	29941478
Aplastic anaemia	96.66	19.61	39	6678	5517	29940244
Synovitis	93.28	19.61	45	6672	9738	29936023
Erythema	89.43	19.61	98	6619	77353	29868408
Tendonitis	82.82	19.61	39	6678	7997	29937764
Alanine aminotransferase abnormal	80.85	19.61	28	6689	2591	29943170
Loss of personal independence in daily activities	71.85	19.61	50	6667	21485	29924276
Psoriatic arthropathy	58.27	19.61	39	6678	15722	29930039
Aspartate aminotransferase increased	51.27	19.61	67	6650	63355	29882406
Alanine aminotransferase increased	50.28	19.61	72	6645	74204	29871557
Nausea	50.20	19.61	163	6554	296794	29648967
Lymphocyte percentage decreased	48.19	19.61	18	6699	2068	29943693
Platelet transfusion	44.14	19.61	14	6703	984	29944777
Treatment failure	43.65	19.61	46	6671	34633	29911128
Heart rate irregular	42.13	19.61	29	6688	12230	29933531
Urine abnormality	41.94	19.61	15	6702	1524	29944237
Febrile neutropenia	40.73	19.61	80	6637	106613	29839148
Victim of child abuse	40.43	19.61	10	6707	280	29945481
Neutrophil percentage increased	39.14	19.61	15	6702	1849	29943912
Lymphocyte count decreased	36.76	19.61	32	6685	19023	29926738
Congenital skin dimples	35.35	19.61	8	6709	151	29945610
Blood pressure fluctuation	34.99	19.61	30	6687	17473	29928288
Death	29.94	19.61	22	6695	357261	29588500
Drug intolerance	29.29	19.61	43	6674	45248	29900513
C-reactive protein increased	29.17	19.61	42	6675	43431	29902330
Epispadias	28.98	19.61	7	6710	177	29945584
Transfusion	28.86	19.61	19	6698	7442	29938319
pH urine increased	28.82	19.61	6	6711	75	29945686
Drug hypersensitivity	28.09	19.61	53	6664	68466	29877295
Child abuse	27.71	19.61	7	6710	214	29945547
White blood cells urine positive	27.11	19.61	10	6707	1109	29944652
Vomiting	27.06	19.61	109	6608	219709	29726052
Headache	25.36	19.61	94	6623	182212	29763549
Pyloric stenosis	25.06	19.61	8	6709	574	29945187
Urine leukocyte esterase positive	24.80	19.61	7	6710	329	29945432
Contraindicated product administered	23.73	19.61	24	6693	17207	29928554
Red blood cell elliptocytes present	22.58	19.61	5	6712	85	29945676
Foetal exposure during pregnancy	22.39	19.61	34	6683	36837	29908924
Red cell distribution width increased	22.38	19.61	13	6704	4081	29941680
Respiratory depression	21.54	19.61	19	6698	11484	29934277
Specific gravity urine increased	21.45	19.61	5	6712	108	29945653
Band neutrophil percentage increased	21.28	19.61	5	6712	112	29945649
Urine ketone body present	20.99	19.61	8	6709	971	29944790
Peripheral motor neuropathy	20.05	19.61	9	6708	1650	29944111

Pharmacologic Action:

Source	Code	Description
CHEBI has role	CHEBI:37955	h1-receptor blockers
CHEBI has role	CHEBI:50919	antiemetico
MeSH PA	D000932	Antiemetics
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D005765	Gastrointestinal Agents
MeSH PA	D018494	Histamine Agents
MeSH PA	D006633	Histamine Antagonists
MeSH PA	D006634	Histamine H1 Antagonists
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D018373	Peripheral Nervous System Agents

Drug Use (View source of the data)

Disease	Relation	SNOMED_ID	DOID
Nausea and vomiting	indication	16932000
Motion sickness	indication	37031009	DOID:2951
Vertigo	indication	399153001
Vomiting	indication	422400008
Nausea	indication	422587007
Prevention of Motion Sickness	indication
Prevention of Nausea and Vomiting	indication
Ménière's disease	off-label use	13445001	DOID:9849
Ocular hypertension	contraindication	4210003	DOID:9282
Hypophosphatemia	contraindication	4996001
Alcoholism	contraindication	7200002
Peptic ulcer	contraindication	13200003	DOID:750
Myocardial infarction	contraindication	22298006	DOID:5844
Hyperthyroidism	contraindication	34486009	DOID:7998
Hypertensive disorder	contraindication	38341003	DOID:10763
Low blood pressure	contraindication	45007003
Blood coagulation disorder	contraindication	64779008	DOID:1247
Diabetes mellitus	contraindication	73211009	DOID:9351
Hyperglycemia	contraindication	80394007	DOID:4195
Chronic idiopathic constipation	contraindication	82934008
Gout	contraindication	90560007	DOID:13189
Liver function tests abnormal	contraindication	166603001
Arterial hemorrhage	contraindication	234003006
Disease of liver	contraindication	235856003	DOID:409
Bladder outflow obstruction	contraindication	236645006
Pyloric obstruction	contraindication	244815007
Benign prostatic hyperplasia	contraindication	266569009
Retention of urine	contraindication	267064002
Thrombocytopenic disorder	contraindication	302215000	DOID:1588
Angle-closure glaucoma	contraindication	392291006	DOID:13550
Acute coronary syndrome	contraindication	394659003
Disorder of coronary artery	contraindication	414024009

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Histamine H1 receptor	GPCR	P35367	HRH1_HUMAN	ANTAGONIST	Ki	7.43		DRUG MATRIX	CHEMBL
Sigma non-opioid intracellular receptor 1	Membrane receptor	Q99720	SGMR1_HUMAN		Ki	6.31		DRUG MATRIX
Sodium-dependent noradrenaline transporter	Transporter	P23975	SC6A2_HUMAN		Ki	5.69		DRUG MATRIX
5-hydroxytryptamine receptor 2A	GPCR	P28223	5HT2A_HUMAN		Ki	6.70		DRUG MATRIX
5-hydroxytryptamine receptor 2B	GPCR	P41595	5HT2B_HUMAN		Ki	5.96		DRUG MATRIX
5-hydroxytryptamine receptor 2C	GPCR	P28335	5HT2C_HUMAN		Ki	6.48		DRUG MATRIX
Alpha-2B adrenergic receptor	GPCR	P18089	ADA2B_HUMAN		Ki	5.60		DRUG MATRIX
Muscarinic acetylcholine receptor M1	GPCR	P11229	ACM1_HUMAN		Ki	6.96		DRUG MATRIX
Muscarinic acetylcholine receptor M2	GPCR	P08172	ACM2_HUMAN		Ki	6.79		DRUG MATRIX
Muscarinic acetylcholine receptor M3	GPCR	P20309	ACM3_HUMAN		Ki	7.02		DRUG MATRIX
Muscarinic acetylcholine receptor M4	GPCR	P08173	ACM4_HUMAN		Ki	7.10		DRUG MATRIX
Muscarinic acetylcholine receptor M5	GPCR	P08912	ACM5_HUMAN		Ki	6.64		DRUG MATRIX
Sodium-dependent dopamine transporter	Transporter	Q01959	SC6A3_HUMAN		Ki	5.75		DRUG MATRIX
Cytochrome P450 2D6	Enzyme	P10635	CP2D6_HUMAN		IC50	5.82		DRUG MATRIX
Alpha-2A adrenergic receptor	GPCR	P08913	ADA2A_HUMAN		Ki	5.79		DRUG MATRIX
Alpha-1D adrenergic receptor	GPCR	P25100	ADA1D_HUMAN		Ki	5.85		DRUG MATRIX

External reference:

ID	Source
4018048	VUID
N0000146389	NUI
D00520	KEGG_DRUG
4018048	VANDF
C0012381	UMLSCUI
CHEBI:4604	CHEBI
CHEMBL1200406	ChEMBL_ID
DB00985	DRUGBANK_ID
10660	PUBCHEM_CID
D004111	MESH_DESCRIPTOR_UI
61	INN_ID
JB937PER5C	UNII
151666	RXNORM
1568	MMSL
4605	MMSL
6646	MMSL
d00861	MMSL
003371	NDDF
387469006	SNOMEDCT_US
81073007	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Wal-Dram	HUMAN OTC DRUG LABEL	1	0363-0198	TABLET	50 mg	ORAL	OTC MONOGRAPH FINULLL	15 sections
Wal-Dram	HUMAN OTC DRUG LABEL	1	0363-0198	TABLET	50 mg	ORAL	OTC MONOGRAPH FINULLL	15 sections
Driminate	HUMAN OTC DRUG LABEL	1	0904-2051	TABLET	50 mg	ORAL	OTC monograph final	15 sections
Driminate	HUMAN OTC DRUG LABEL	1	0904-2051	TABLET	50 mg	ORAL	OTC monograph final	15 sections
Dimenhydrinate	HUMAN OTC DRUG LABEL	1	0904-6772	TABLET	50 mg	ORAL	OTC monograph final	16 sections
PhysiciansCare DimenhydrinateMotion Sickness Relief	HUMAN OTC DRUG LABEL	1	0924-1006	TABLET, COATED	50 mg	ORAL	OTC monograph final	16 sections
Dimenhydrinate	HUMAN OTC DRUG LABEL	1	0924-1007	TABLET	50 mg	ORAL	OTC monograph final	17 sections
Motion Sickness	HUMAN OTC DRUG LABEL	1	11673-198	TABLET	50 mg	ORAL	OTC MONOGRAPH FINULLL	15 sections
Motion Sickness	HUMAN OTC DRUG LABEL	1	11673-198	TABLET	50 mg	ORAL	OTC MONOGRAPH FINULLL	15 sections
Motion Sickness Relief	HUMAN OTC DRUG LABEL	1	11822-0198	TABLET	50 mg	ORAL	OTC MONOGRAPH FINULLL	15 sections
Motion Sickness Relief	HUMAN OTC DRUG LABEL	1	11822-0198	TABLET	50 mg	ORAL	OTC MONOGRAPH FINULLL	15 sections
Motion Sickness	HUMAN OTC DRUG LABEL	1	15127-262	TABLET	50 mg	ORAL	OTC MONOGRAPH FINULLL	15 sections
Motion Sickness	HUMAN OTC DRUG LABEL	1	15127-262	TABLET	50 mg	ORAL	OTC MONOGRAPH FINULLL	15 sections
Motion SicknessRelief	HUMAN OTC DRUG LABEL	1	24385-004	TABLET	50 mg	ORAL	OTC MONOGRAPH FINULLL	15 sections
Motion Sickness Relief	HUMAN OTC DRUG LABEL	1	36800-930	TABLET	50 mg	ORAL	OTC MONOGRAPH FINULLL	15 sections
Motion Sickness Relief	HUMAN OTC DRUG LABEL	1	36800-930	TABLET	50 mg	ORAL	OTC MONOGRAPH FINULLL	15 sections
Motion Sickness Relief	HUMAN OTC DRUG LABEL	1	46122-536	TABLET	50 mg	ORAL	OTC monograph final	15 sections
Motion Sickness Relief	HUMAN OTC DRUG LABEL	1	46122-536	TABLET	50 mg	ORAL	OTC monograph final	15 sections
Motion Sickness Relief	HUMAN OTC DRUG LABEL	1	49035-981	TABLET	50 mg	ORAL	OTC MONOGRAPH FINULLL	15 sections
Motion Sickness Relief	HUMAN OTC DRUG LABEL	1	49035-981	TABLET	50 mg	ORAL	OTC MONOGRAPH FINULLL	15 sections
DIMENHYDRINULLTE	HUMAN OTC DRUG LABEL	1	49483-352	TABLET, FILM COATED	50 mg	ORAL	OTC monograph final	11 sections
Airmit Ace	HUMAN OTC DRUG LABEL	1	49873-802	TABLET	25 mg	ORAL	OTC monograph final	12 sections
Motion Sickness	HUMAN OTC DRUG LABEL	1	50804-198	TABLET	50 mg	ORAL	OTC MONOGRAPH FINULLL	15 sections
Motion Sickness	HUMAN OTC DRUG LABEL	1	50804-198	TABLET	50 mg	ORAL	OTC MONOGRAPH FINULLL	15 sections
Motion SicknessOriginal Formula	HUMAN OTC DRUG LABEL	1	50804-630	TABLET	50 mg	ORAL	OTC MONOGRAPH FINULLL	15 sections
Motion Sickness Relief	HUMAN OTC DRUG LABEL	1	50844-199	TABLET	50 mg	ORAL	OTC MONOGRAPH FINULLL	15 sections
Motion Sickness Relief	HUMAN OTC DRUG LABEL	1	50844-199	TABLET	50 mg	ORAL	OTC MONOGRAPH FINULLL	15 sections
Motion Sickness	HUMAN OTC DRUG LABEL	1	55315-630	TABLET	50 mg	ORAL	OTC MONOGRAPH FINULLL	15 sections
Motion Sickness	HUMAN OTC DRUG LABEL	1	59779-198	TABLET	50 mg	ORAL	OTC monograph final	15 sections
Motion Sickness	HUMAN OTC DRUG LABEL	1	59779-198	TABLET	50 mg	ORAL	OTC monograph final	15 sections